Literature DB >> 29704676

Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.

Léon C van Kempen1, Hangjun Wang2, Maria Leonor Aguirre3, Alan Spatz4, Goulnar Kasymjanova5, Juliana F Vilacha6, Matthew R Groves6, Jason Agulnik7, David Small7.   

Abstract

Entities:  

Keywords:  Afatinib; EGFR triple mutation; Osimertinib; P794L mutation NSCLC

Mesh：

Substances：

Year:  2018        PMID： 29704676     DOI： 10.1016/j.jtho.2018.04.020

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.

Authors:  Yang Yang; Qilong Liu; Lei Cao; Wei Sun; Xiaowei Gu; Bin Liu; Na Xiao; Fei Teng; Xiaoli Li; Meiji Chen; Weiguang Yu; Huanyi Lin; Guixing Xu
Journal:  BMC Pulm Med       Date:  2021-05-19       Impact factor: 3.317

2.  EGFR and BRAF mutations in inverted sinonasal papilloma - a more complex landscape?

Authors:  Sarah Zonnur; Andreas Erbersdobler; Björn Schneider
Journal:  Virchows Arch       Date:  2020-10-13       Impact factor: 4.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.